NOVEL THERAPEUTIC FOR THE TREATMENT OF PARKINSONS DISEASE

Projektinformationen

IRL790

ID Finanzhilfevereinbarung: 835463

DOI

10.3030/835463

Projekt abgeschlossen

EK-Unterschriftsdatum 26 November 2018

Startdatum 1 November 2018

Enddatum 28 Februar 2019

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB
Sweden

Periodic Reporting for period 1 - IRL790 (NOVEL THERAPEUTIC FOR THE TREATMENT OF PARKINSONS DISEASE)

Berichtszeitraum: 2018-11-01 bis 2019-02-28

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

IRLAB’s goal is to develop a successful treatment that combats severe motor and psychotic symptoms in Parkinson’s disease (PD). PD is a debilitating neurodegenerative disorder affecting more than 6 million people worldwide. It is a neurological disorder with one of the highest increases in death rates, prevalence, and disability-adjusted life-years (DALYs). Levodopa, introduced more than 50 years ago, remains the most prescribed treatment for the symptomatic relief of PD, although its long-term is strongly associated to the development of motor complications, i.e. levodopa-induced dyskinesia (PD-LIDs) and psychosis in PD (PD-P). PD-P is both treatment-related and has disease-related components as well.
The overall objectives of this SME Phase 1 project were to optimise the business plan that will guide the exploitation and commercialisation of IRLAB’s novel candidate drug IRL790. It is a First in Class drug that offers improvements in both motor (LIDs) and mental (psychosis) symptom domains without exacerbating parkinsonism. Other goals were to analyse competitive landscape, prepare detailed plans for the clinical studies, and assess IRL790’s potential for the company’s growth.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

The feasibility assessment included three major parts: 1) Clinical and technical feasibility evaluation, 2) Market feasibility assessment, and 3) Business Strategy Development. The overall results show that it is market-wise and clinically justified to pursue this innovation project further and enter a Phase II clinical study in PD-P patients. IRL790 is of strategic importance to IRLAB as it offers high revenue potential and its success will further strengthen the company’s growth and investment into R&D.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

This feasibility study has confirmed the innovative character of IRLAB’s approach. Basing on the proprietary discovery platform, IRLAB has successfully developed a candidate drug with tremendous potential to improve intervention outcomes for PD patients with psychosis and LIDs. IRL790’s safety, toxicology and tolerability have been validated in comprehensive regulatory GLP safety and toxicology program and in Phase I clinical trials. Its therapeutic efficacy in PD-LIDs is being evaluated in an ongoing Phase II study.
Besides medical benefits to patients, IRL790 has also the potential to bring cost-savings to healthcare providers by effectively reducing Parkinson’s disease burden.

The integrative and parallel decision model of ISP, IRLAB's unique discovery platform